HAYA Therapeutics

Lead the Platform that Makes Innovation Possible — From San Diego. HAYA is looking for a hands-on IT leader who can support teams across continents. As Manager, IT, you’ll shape and secure the platforms driving our science forward, from onboarding laptops to managing GPU-enabled servers for AI-based discovery. Join us in shaping the future of precision medicine 🚀 ➡️ Apply today - https://lnkd.in/eQqcpgUf   #BiotechJobs #HAYATherapeutics #ITJobs #TechCareers #CloudComputing #InfrastructureEngineering #BiotechIT #IT #SanDiego

At HAYA Therapeutics, every day is RNA Day (August 1)! 🧬 Ribonucleic Acid (RNA) isn't merely a molecular messenger conveying information from our DNA; it's a fundamental building block of life itself. Over the past three decades, scientific discoveries have unveiled various classes of RNA molecules that play pivotal roles in gene expression and regulation. Today, RNA emerges as a multifaceted player in evolution and cell biology, as well as a game-changer in therapeutics. ➡️ Learn more: https://lnkd.in/e23PCc22 At HAYA, we are harnessing disease-causing lncRNAs to advance a new class of RNA medicines. Beyond symptoms management, our approach reprograms disease-driving cell states back to a healthy state, restoring tissue health and addressing complex disease at its roots. Let's celebrate the power of RNA, today and every day! 🌟🧬 #WorldRNADay #RNA #lncRNA #Therapeutics #PrecisionMedicine #RNAMedicines #HealthcareInnovation #HAYA #RNAday

My daughter, Eva Shin, sent me this article from Massachusetts General Hospital about Peter Horsman, a patient with Hypertrophic Cardiomyopathy (HCM). Former colleagues J. Sawalla Guseh, II, Dr. Aaron Baggish, and Katie Stewart, MS, NP listened carefully, analyzed the data, and developed a plan to enable him to conquer the tallest mountain in the world! At HAYA Therapeutics, our lead program targets the unmet need in HCM. Stories like Peter's are truly inspiring. https://lnkd.in/eXWiZ4jF

The dark genome—long overlooked—is now emerging as a powerful new frontier for therapeutic innovation. It’s encouraging to see growing recognition of this space, as highlighted in a recent article exploring how AI can help map and interpret this vast, uncharted territory. At HAYA Therapeutics, we are pioneering this landscape by unlocking the regulatory genome to reprogram cell state—shifting diseased cells back to health. By targeting long noncoding RNAs (lncRNAs), we’re developing a new class of RNA medicines aimed at the root causes of common and chronic diseases. We’re proud to be at the forefront of this potential revolution in drug discovery and development. https://lnkd.in/em4JWnzy

📣 HAYA Therapeutics to present at Strüngmann Award Ceremony 2025! We’re thrilled to share that Daniel Blessing, HAYA’s CTO & co-founder, will be presenting HAYA’s latest updates at the 2025 Strüngmann Award Ceremony. Alongside HAYA’s CEO & Co-founder, Samir Ounzain, Daniel was selected as the inaugural winner of the Strüngmann Award 2024 edition- a proud moment for our entire team.   This award recognizes life science entrepreneurs driving transformative innovation across the DACH region (Germany, Austria, and Switzerland) and initiated to honor Dr. Andreas Strüngmann and Dr. Thomas Strüngmann for their inspiring entrepreneurial achievements and visionary investments. 🚀   We’re looking forward to connecting with this inspiring group of innovators and learn firsthand who the winner of the 2025 Strüngmann Award will be. Vielen, vielen dank to ATHOS and congratulations to all this year's finalists! 👏   ➡️ For more information about the award and this year's 2025 nominees, please visit: https://lnkd.in/e4FGshmC   # StrungmannAward #2025 #LifeSciences #DACH #entrepreneur #vision #biotech #HAYA #Regulatory Genome

https://lnkd.in/eM5RxVrA

The World Economic Forum has just announced the names of the 100 most promising Technology Pioneers for 2025. These companies are tackling global challenges by developing revolutionary technologies. Among the winners are Haya Therapeutics and Neural Concept. Biotech company HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. Samir Ounzain Daniel Blessing AI startup Neural Concept leverages neural networks and deep learning techniques to generate optimized design and engineering processes for a wide range of applications in the engineering Pierre Baqué Philippe Cuendet field. https://lnkd.in/eGCbx2kG

🚀 We’re thrilled to share that HAYA Therapeutics is among the 100 early-stage companies included in the 2025 cohort of the World Economic Forum’s Technology Pioneers! Being part of the World Economic Forum 2025 Technology Pioneers cohort is an important recognition of our regulatory genome platform and pipeline dedicated to advancing the next-generation of disease-modifying precision medicines that addresses the root cause of disease, by reprogramming disease-driving cell-states into healthy ones. 🧬 Our energy is renewed, and our dedication to delivering safer, more effective medicines to patients remains stronger than ever! ✨ To every company in the 2025 cohort—congratulations! ➡️ Learn more: https://lnkd.in/eaN2ii9M Follow us and stay tuned for more exciting news! #WEF #techpioneers25 #Innovation #technologies #HAYA #HAYATherapeutics #RegulatoryGenome #lncRNAs #2025Cohort #PrecisionMedicines #RNATherapeutics #Impact #ReprogrammingCells

📣 HAYA Therapeutics to Speak at the 23rd Fraunhofer ITEM Seminar “Models of Lung Disease 2025”!   HAYA’s Senior R&D Program lead, Alexandra Iouranova will be presenting the 23rd Fraunhofer Seminar “Models of Lung Disease 2025, taking place in Hannover, Germany, June 19-20! This event will bring together leading experts from academia and industry to discuss the latest advancements in lung disease models, lung fibrosis pathogenesis and therapeutics. 🫁   Ready to discover how HAYA Therapeutics is leveraging the regulatory genome to advance next-generation of disease-modifying therapies for lung disease? 🧬 Join us this Friday, June 20, at 8:30am CEST to learn more! ➡️ https://lnkd.in/eib4bAWp   See you in Hannover! 🇩🇪   #FraunhoferITEM #MLD2025 #Lung #LungModels #LungFibrosis #RNATherapeutics #HAYA #RegulatoryGenome #lncRNAs

🚀 We’re excited to announce that HAYA Therapeutics will be participating at the Dark Genome Target Discovery & Development Summit 2025!   This is a brand-new, industry-focused meeting that dives into the potential therapeutic promise of the dark genome and discusses the latest breakthroughs in the field from target discovery to drug development.   Join, HAYA’s CEO & co-founder Samir Ounzain to explore how this 98% of the human genome is providing new insights into disease biology and paving the way for next-generation disease-modifying therapeutics. 🧬   🗓️ Tuesday, June 17th | 08:30am EDT for the Panel Discussion: “Pioneers’ Fireside Chat: Shedding a Light on the Value of the Dark Genome to Raise Awareness & Educate the Wider Community”   🗓️ Wednesday, June 18th | 10:45am EDT for a Presentation: “Translating Discovery of Novel LncRNA Targets into Clinical Programs”   ➡️ Learn more: https://lnkd.in/evPc6DZs See you in Boston!   Hanson Wade #DarkGenome #HAYA #HAYATherapeutics #RegulatoryGenome #Genomics #DrugDiscovery #Biotech #LifeSciences #Innovation #Healthcare #RNATherapeutics #lncRNA #Networking #Boston